Regencell Bioscience Holdings Limited
HealthcareNASDAQ:RGC · NASDAQ Capital Market
-$0.69 today
Vol 0.08M · Avg 0.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.7%
avg -19.0%
ROIC
-69.8%
avg -19.4%
ROA
-62.3%
avg -130.8%
Analysis
ROA is currently the strongest return metric at -62.3% versus its period average of -130.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Wai Hong Chung | Chief Operating Officer, Chief Strategy Officer & Director | $245,642.00 | — | 48 | $0.00 | <0.01% |
Yat-Gai Au | Founder, Chairman & Chief Executive Officer | — | — | 53 | $581,514.00 | 0.12% |
Yat-Pui Au | Chief Business Officer | — | — | 51 | $581,514.00 | 0.12% |
Antonia Assang | Senior Vice President of Project Management | — | — | — | — | — |
Michelle Chan | Financial Controller, Chief Financial Officer & Principal Financial Officer | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.21B
Masimo Corporation
NASDAQ:MASI
$9.42B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.70B
AptarGroup, Inc.
NYSE:ATR
$7.54B
Merus N.V.
MRUS
$6.83B
Grifols, S.A.
NASDAQ:GRFS
$6.50B
Abivax S.A.
NASDAQ:ABVX
$6.35B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.04B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
Who manages RGC?
Regencell Bioscience Holdings Limited (RGC) lists 5 active executives. The top listed executive is Yat-Gai Au, Founder, Chairman & Chief Executive Officer.
Are RGC insiders buying or selling?
Recent insider activity shows net selling of $1.47B.
Explore More
Continue the stock analysis
Jump to another research area for this company.